UCHL5 and Waldenstrom macroglobulinemia: In addition, US14/UCHL5 inhibitors could cause specific apoptosis in bortezomib or ibrutinib-resistant Waldenstrom macroglobulinemia cells, suggesting that USP14 could be used as a new therapeutic target for Waldenstrom macroglobulinemia 25.